Company Filing History:
Years Active: 2012
Title: Michael Gerard Gallagher: Innovator in Pharmaceutical Chemistry
Introduction
Michael Gerard Gallagher is a notable inventor based in Newhouse, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target AMPA receptors. His work is crucial for advancing therapies for various psychiatric diseases.
Latest Patents
Gallagher holds a patent for "Substituted thieno[2,3-d]pyrimidines as AMPA modulators." This invention relates to a heterocyclic derivative, defined by specific variables, or to a pharmaceutically acceptable salt or solvate thereof. The patent also encompasses a pharmaceutical composition that includes these heterocyclic derivatives and their therapeutic applications. These applications are particularly relevant for treating psychiatric conditions such as schizophrenia, depression, and cognitive disorders like Alzheimer's disease.
Career Highlights
Michael Gallagher is associated with MSD Oss B.V., where he applies his expertise in pharmaceutical development. His innovative work has led to advancements in treatments that enhance synaptic responses mediated by AMPA receptors. This focus on psychiatric diseases highlights his commitment to improving mental health therapies.
Collaborations
Gallagher has collaborated with notable colleagues, including Craig Jamieson and Amanda Jane Lyons. These partnerships have likely contributed to the success of his research and patent developments.
Conclusion
Michael Gerard Gallagher is a distinguished inventor whose work in pharmaceutical chemistry has the potential to transform treatments for psychiatric diseases. His innovative contributions continue to pave the way for advancements in mental health therapies.